We’ve built an entire wellness industry around quantification. Heart rate variability. Sleep architecture. Step counts. VO2 max. Women were early adopters and power users of this movement—tracking cortisol patterns, optimizing nutrient absorption, and investing hundreds of dollars monthly in protocols designed to extend healthspan.
But there’s a glaring omission in all this optimization: We have no idea what’s actually happening in our brains.
Not “we don’t think about it enough.” Not “we should pay more attention.” We literally cannot measure it in any meaningful way outside of a research lab or neurology clinic. And that gap is costing us—individually as women navigating perimenopause and menopause, collectively as a healthcare system, and economically as businesses lose leadership capacity and institutional knowledge.
THE NUMBERS WE IGNORE
Here’s what knocked me sideways. Women in their sixties are twice as likely to develop Alzheimer’s disease over the rest of their lives as breast cancer. I can name five breast cancer awareness campaigns and zero that are focused on women’s cognitive health. Meanwhile, almost two-thirds of all Americans with Alzheimer’s disease are women.
During perimenopause, women experience 11% more brain shrinkage associated with Alzheimer’s disease. Most women going through menopause report problems with memory and concentration. When they bring these concerns to doctors, they hear “just menopause” or “probably stress.”
The Study of Women’s Health Across the Nation followed 2,124 women over nearly seven years and found objective, measurable declines in processing speed and verbal memory during midlife, even after controlling for sleep disturbance, hot flashes, mood symptoms, and practice effects. Something else is happening, tied to hormonal changes.
Women experience cognitive decline symptoms earlier than men but get diagnosed later. We’re symptomatic before we’re believed.
WHY THE MEDICAL ESTABLISHMENT MISSED THIS
The answer is both simple and infuriating: For decades, we weren’t in the studies. For example, in 1977, women of childbearing potential were barred from early-stage drug trials. The rationale was preventing birth defects in potential fetuses, after the thalidomide incidents. The consequence was decades of drug research based almost exclusively on male bodies. Congress didn’t reverse within the National Institutes of Health-funded research until 1993.
For brain health, the gap is even worse. We have no large-scale randomized trials testing whether interventions improve cognitive concerns during perimenopause. None. Most research focuses on postmenopausal women—studying what happened after the damage was done rather than the transition itself. It’s like studying a hurricane’s aftermath without ever measuring wind speed during the storm.
WHAT’S ACTUALLY HAPPENING IN YOUR BRAIN
During menopause, the brain experiences something called hypometabolism—it’s getting less glucose, its primary fuel source. Imaging studies show postmenopausal women have lower gray matter volume and reduced glucose metabolism in the exact regions that matter for memory—the same areas that light up as problematic in Alzheimer’s.
Research suggests that timing is everything. At least one 2010 study indicated that interventions initiated in midlife appear promising for preventing dementia. Wait too long, and you may have missed the window. Yet current guidelines don’t recommend hormone therapy for cognitive concerns, despite this older evidence. Women experiencing real symptoms are left without clear options.
THE MEASUREMENT GAP
The wellness industry has gotten remarkably good at consumer health tracking. My watch tells me my resting heart rate is 52, my HRV was slightly elevated last night, and I got 47 minutes of REM sleep. All useful information. None of it tells me anything about what’s happening cognitively.
Is my brain actually performing well today, or am I just caffeinated enough to fake it? Did that meditation session actually help my cognitive stress response, or did I just sit quietly for 20 minutes, convincing myself I felt calmer? I have genuinely no idea. I’m flying completely blind on the organ running the entire operation.
These tools have value—I use them daily. But measuring brain health through sleep trackers and HRV monitors is like assessing your cardiovascular fitness by looking at your sneakers. Sure, worn-out shoes might suggest you’ve been running, but they’re not telling you anything about your actual cardiac capacity.
EEG technology is starting to change this. What used to require lab coats and wires can now track focus, cognitive processing speed, and stress response continuously and unobtrusively. For the first time, “I think my brain is okay” can become “here’s the actual data.”
WHY THIS MATTERS FOR BUSINESS
Women in their 40s and 50s aren’t just experiencing a medical issue—they’re often at the peak of their career performance. They’re running companies, leading teams, and making strategic decisions that affect hundreds or thousands of people. They represent enormous institutional knowledge and leadership capacity.
When their cognitive symptoms get dismissed as “just stress,” we’re not just failing them medically. We’re losing productivity. We’re hemorrhaging talent. We’re making terrible business decisions about who’s capable and who’s slowing down based on symptoms that might be treatable if taken seriously.
And here’s what really frustrates me: These same women are already investing in health optimization. They’re doing the protocols, taking the supplements, and working with longevity clinics. But without objective data about cognitive function, they have no idea if any of it is working. They’re spending money and time on interventions they cannot validate.
The longevity industry loves talking about extending lifespan. But people don’t actually want more years if those years are cognitively diminished. They want to stay sharp. They want to remain engaged, productive, able to do complex work, and able to maintain relationships. That’s the market, and it’s massive and underserved.
THE OPPORTUNITY
Technology that makes brain health measurement accessible creates immediate opportunities: Women can validate whether their interventions actually work, researchers can finally collect the population-level data they’ve been missing, and businesses can address a massive underserved market that’s already spending money on cognitive health—just blindly.
We don’t wait for fractures to start caring about bone density. We shouldn’t wait for decline to start measuring brain health.
Jessica Randazza Pade is VP of marketing at Neurable.